Evidence map›Paper›PMID 38290090›Full record

SynthesisNeurology2024

Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.

Matthew P Pase, Jayandra J Himali, Raquel Puerta, Alexa S Beiser, Mitzi M Gonzales, Claudia L Satizabal, Qiong Yang, Hugo J Aparicio, Daniel J Kojis, Charles S Decarli and 16 more

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  17. Observational
  18. PeripheralFrontiers in aging neuroscience · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 1 institution in 2 countries.

Matthew P PaseFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-4143-8485
Jayandra J HimaliFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-1391-9481
Raquel PuertaFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Alexa S BeiserFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0001-8551-7778
Mitzi M GonzalesFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-8467-0938
Claudia L SatizabalFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-1115-4430
Qiong YangFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-3658-1375
Hugo J AparicioFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0001-8584-1455
Daniel J KojisFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-5267-0554
Charles S DecarliFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-1914-2693
Oscar L LopezFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-8546-8256
Will LongstrethFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0009-0007-9552-3603
Vilmundur GudnasonFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0001-5696-0084
Thomas H MosleyFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-3343-1352
Joshua C BisFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Alison FohnerFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-4231-3331
Bruce M PsatyFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Mercè BoadaFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-2617-3009
Pablo García-GonzálezFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Sergi ValeroFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-6599-948X
Marta MarquiéFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Russell TracyFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.
Lenore J LaunerFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0002-3238-7612
Agustín RuizFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-2633-2495
Myriam FornageFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0003-0677-8158
Sudha SeshadriFrom the Turner Institute for Brain and Mental Health (M.P.P.), Monash University, Australia; Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases (J.J.H., M.M.G.), University of Texas Health Sciences Center, San Antonio; ACE Alzheimer Center (R.P., M.B., P.G.-G., S.V., M.M., A.R.), Barcelona, Spain; Boston University School of Public Health (A.S.B., D.J.K.), MA; University of Texas Health Sciences Center (C.L.S., S.S.), San Antonio; Department of Neurology (Q.Y., H.J.A.), Boston University School of Medicine, MA; Department of Neurology (C.S.D.), School of Medicine & Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis; Department of Neurology (O.L.L.), School of Medicine, University of Pittsburgh, PA; University of Washington (W.L., B.M.P.), Seattle; Faculty of Medicine (V.G.), University of Iceland, Reykjavík; University of Mississippi Medical Center (T.H.M.), The MIND Center, Jackson; Cardiovascular Health Research Unit (J.C.B.), Department of Medicine, and Department of Epidemiology (A.F.), University of Washington, Seattle; University of Vermont (R.T.), Burlington; Laboratory of Epidemiology and Population Sciences (L.J.L.), National Institute on Aging, NIH, Bethesda, MD; and University of Texas Health Science Center (M.F.), Houston. Matthew P. Pase is currently at the School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Australia.ORCID 0000-0001-6135-2622
Turing Institute · GB

Funding

ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028U01HL096812 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, THOMAS H MOSLEY · 2010 to 2026
$65.7M
FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN · 2019 to 2024
$29.8M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Blake B Rasmussen · 2015 to 2026
$14.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5U01HL096917 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI MOSLEY, THOMAS H · 2010 to 2018
$11.9M
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and ResilienceR01AG066524 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KASHANI, AMIR H, RAMACHANDRAN, VASAN S · 2020 to 2024
$9.7M
ARIC Neurocognitive Study (ARIC-NCS) Renewal UNC 4 of 5U01HL096899 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J · 2010 to 2018
$7.5M
ARIC Neurocognitive Study (ARIC-NCS)U01HL096902 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2010 to 2018
$7.4M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 4 of 5U01HL096814 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUGHES, TIMOTHY M., WAGENKNECHT, LYNNE E · 2010 to 2018
$6.5M
NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS HHSN268201500001INHLBI NIH HHS HHSN268201800003INHLBI NIH HHS HHSN268201800004INHLBI NIH HHS HHSN268201800005INHLBI NIH HHS HHSN268201800006INHLBI NIH HHS HHSN268201800007INHLBI NIH HHS U01 HL096812NHLBI NIH HHS U01 HL096814NHLBI NIH HHS U01 HL096899NHLBI NIH HHS U01 HL096902NHLBI NIH HHS U01 HL096917NIA NIH HHS K01 AG071689NIA NIH HHS P30 AG066546NIA NIH HHS R01 AG049607NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG059421NIA NIH HHS R01 AG066524NIDA NIH HHS HHSN271201200022CNINDS NIH HHS L30 NS093634NINDS NIH HHS R01 NS017950NINDS NIH HHS U01 NS125513NINDS NIH HHS UF1 NS125513NINDS NIH HHS UH2 NS100605NINDS NIH HHS UH3 NS100605
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHigher YKL-40 levels in the CSF are a known biomarker of brain inflammation. We explored the utility of plasma YKL-40 as a biomarker for accelerated brain aging and dementia risk.

methodsWe performed cross-sectional and prospective analyses of 4 community-based cohorts in the United States or Europe: the Age, Gene/Environment Susceptibility-Reykjavik Study, Atherosclerosis Risk in the Communities study, Coronary Artery Risk Development in Young Adults study, and Framingham Heart Study (FHS). YKL-40 was measured from stored plasma by a single laboratory using Mesoscale Discovery with levels log transformed and standardized within each cohort. Outcomes included MRI total brain volume, hippocampal volume, and white matter hyperintensity volume (WMHV) as a percentage of intracranial volume, a general cognitive composite derived from neuropsychological testing (SD units [SDU]), and the risk of incident dementia. We sought to replicate associations with dementia in the clinic-based ACE csf cohort, which also had YKL-40 measured from the CSF.

resultsMeta-analyses of MRI outcomes included 6,558 dementia-free participants, and for analysis of cognition, 6,670. The blood draw preceded MRI/cognitive assessment by up to 10.6 years across cohorts. The mean ages ranged from 50 to 76 years, with 39%-48% male individuals. In random-effects meta-analysis of study estimates, each SDU increase in log-transformed YKL-40 levels was associated with smaller total brain volume (β = -0.33; 95% CI -0.45 to -0.22; DISCUSSION: Higher plasma YKL-40 levels were associated with lower brain volume, poorer cognition, and incident dementia. Plasma YKL-40 may be useful for studying the association of inflammation and its treatment on dementia risk.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDementiaAgedBiomarkersBrainChitinase-3-Like Protein 1CognitionCross-Sectional StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1

Identifiers

PMID38290090
PMCPMC11383876
OpenAlexW4391373955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.